1199-60-6

Usage

Chemical compound

4H-Pyran-2-carboxylic acid, 5-methoxy-4-oxo-

Upstream product

• 6269-25-6 2-Hydroxymethyl-5-methoxy-4H-pyran-4-on 
• 499-78-5 comenic acid 
• 77-78-1 dimethyl sulfate 
• 501-30-4 5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one 
• 35438-43-8 5-methoxy-4H-pyran-4-one-2-carboxaldehyde 
• 74-88-4 methyl iodide 

Downstream Products

• 353460-76-1 5-methoxy-1-methyl-4-oxo-1,4-dihydro-pyridine-2-carboxylic acid 
• 1394231-88-9 N-(2-(tert-butyldiphenylsiloxy)ethyl)-6-(2-(6-chloroquinolin-2-yl)thiazol-4-yl)-5-methoxy-1-methyl-3-(methylthio)-4-oxo-1,4-dihydropyridine-2-carboxamide 
• 1394231-79-8 (2-(tert-butyldiphenylsilyloxy)ethyl)-5-methoxy-N-methyl-4-oxo-1,4-dihydropyridine-2-carboxamide 
• 1394231-80-1 (2-(tert-butyldiphenylsilyloxy)ethyl)-5-methoxy-N,6-dimethyl-4-oxo-1,4-dihydropyridine-2-carboxamide 
• 1394231-81-2 (2-(tert-butyldiphenylsilyloxy)ethyl)-6-iodo-5-methoxy-N-methyl-4-oxo-1,4-dihydropyridine-2-carboxamide 
• 1394231-82-3 3-bromo-(2-(tert-butyldiphenylsilyloxy)ethyl)-5-methoxy-N-methyl-4-oxo-1,4-dihydropyridine-2-carboxamide 
• 1394231-83-4 (2-(tert-butyldiphenylsilyloxy)ethyl)-5-methoxy-N-methyl-3-(methylthio)-4-oxo-1,4-dihydropyridine-2-carboxamide 
• 1394231-84-5 (2-(tert-butyldiphenylsilyloxy)ethyl)-6-iodo-5-methoxy-N-methyl-3-(methylthio)-4-oxo-1,4-dihydropyridine-2-carboxamide 
• 1394231-78-7 (2-(tert-butyldiphenylsilyloxy)ethyl)-5-methoxy-4-oxo-4H-pyran-2-carboxamide 
• 1193-64-2 3-methoxy-4H-pyran-4-one 
• 50700-60-2 3-methoxy-4(1H)-pyridone 
• 5878-19-3 Methoxyacetone 
• 144-62-7 oxalic acid 
• 857433-67-1 methyl 4-chloro-5-methoxypyridine-2-carboxylate 

Relevant academic research and scientific papers

Rational design, synthesis and biological evaluation of novel multitargeting anti-AD iron chelators with potent MAO-B inhibitory and antioxidant activity

A series of (3-hydroxypyridin-4-one)-coumarin hybrids were developed and investigated as potential multitargeting candidates for the treatment of Alzheimer's disease (AD) through the incorporation of iron-chelating and monoamine oxidase B (MAO-B) inhibition. This combination endowed the hybrids with good capacity to inhibit MAO-B as well as excellent iron-chelating effects. The pFe3+ values of the compounds were ranging from 16.91 to 20.16, comparable to more potent than the reference drug deferiprone (DFP). Among them, compound 18d exhibited the most promising activity against MAO-B, with an IC50 value of 87.9 nM. Moreover, compound 18d exerted favorable antioxidant activity, significantly reversed the amyloid-β1-42 (Aβ1-42) induced PC12 cell damage. More importantly, 18d remarkably ameliorated the cognitive dysfunction in a scopolamine-induced mice AD model. In brief, a series of hybrids with potential anti-AD effect were successfully obtained, indicating that the design of iron chelators with MAO-B inhibitory and antioxidant activities is an attractive strategy against AD progression.

Synthetic method for amino-containing hydroxypyridone compound

The invention discloses a synthetic method for an amino-containing 3-hydroxypyridine-4-ketone iron chelating agent as shown in a formula (III) which is described in the specification. The synthetic method comprises the following steps: with methyl-protected azido hydroxypyridone as shown in a formula (I) which is described in the specification as a raw material, allowing the methyl-protected azido-hydroxypyridine to generate reduction and demethylation reactions under the protection of boron tribromide as shown in a formula (II) which is described in the specification, a solvent A and gas B, after completion of the reactions, carrying out quenching with a solvent C, and carrying out post-treatment so as to obtain the amino-containing 3-hydroxypyridine-4-ketone compound as shown in the formula (III). Compared with a conventional method, the synthetic method provided by the invention adopts a boron tribromide reagent with mild reaction conditions, avoids the use of a metal catalyst, andhas simple and convenient operation and high reaction yield.

6-MEMBERED HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

A compound represented by Formula (I): wherein or the like Y1 is O or the like; Z1 is C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; R2a, R2b, R2c and R2d are each independently a hydrogen atom or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is or the like Ring B is a 6-membered aromatic carbocycle or the like; R9a and R10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p1 is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.

NITROGEN-CONTAINING HETEROCYCLIC COMPOUND

The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as a medicament such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the attached DESCRIPTION.

Systematic comparison of the mono-, dimethyl-and trimethyl 3-hydroxy-4(1H)-pyridones-Attempted optimization of the orally active iron chelator, deferiprone

A range of close analogues of deferiprone have been synthesised. The group includes mono-, di-and trimethyl-3-hydroxy-4(1H)-pyridones. These compounds were found to possess similar pFe3+ values to that of deferiprone, with the exception of the 2.5-dimethylated derivatives. Surprisingly the NHcontaining hydroxy-4(1H)-pyridones were found to be marginally more lipophilic than the corresponding N-Me containing analogues. This same group are also metabolised less efficiently by Phase 1 hydroxylating enzymes than the corresponding N-Me analogues. As result of this study, three compounds have been identified for further investigation centred on neutropenia and agranulocytosis.

Total synthesis of lodopyridone

A convergent total synthesis of the structurally unprecedented alkaloid lodopyridone was achieved using a cross-coupling of an iodopyridone fragment with a quinolinethiazolylstannane. Key features of the syntheses of the pentasubstituted 4-pyridone were a

NOVEL PYRONE-INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION

The present invention relates to novel pyrone-indole derivatives, pharmaceutical formulations containing them, and use of the compounds in the manufacture of Medicaments for treating or preventing various diseases.